Skin Clearance and Itch Relief in Black or African American Patients With Moderate-to-Severe Atopic Dermatitis Treated With Upadacitinib: 140-Week Outcomes from Integrated Phase 3 Measure Up 1 and 2 Studies. J of Skin 2025, 9 (6), s615. https://doi.org/10.25251/9qs79351.